Phase Holographic (PHI) Q4 2025 earnings summary

Executive summary

• Net sales for Q4 rose to 5,580 KSEK from 1,686 KSEK year-over-year, with full-year sales at 16,646 KSEK, up from 10,510 KSEK.

• Gross margin improved to 79% in Q4 (from 60%) and 74% for the year (from 71%).

• Operating losses narrowed for the year, with net result at -17,519 KSEK versus -20,175 KSEK prior year.

• CEO transition occurred during the period, with Patrik Eschricht returning to lead.

• A fully subscribed rights issue raised SEK 64.3 million, strengthening financial position.

Financial highlights

• EBITDA for Q4 was -3,562 KSEK (vs. -2,719 KSEK), and for the year -12,071 KSEK (vs. -13,443 KSEK).

• Earnings per share improved to -0.08 SEK in Q4 (from -0.22 SEK) and -0.40 SEK for the year (from -0.81 SEK).

• Cash and equivalents at period end were 14,443 KSEK, up from 167 KSEK year-over-year.

• Equity ratio increased to 87% from 15% year-over-year.

Outlook and guidance

• Strategic focus on clinical integration, product innovation, and global expansion, especially in North America and Asia.

• Continued development of HoloMonitor® CellSync system and AI-driven features.

• Plans to expand into regenerative medicine and clinical research markets.